Exploiting Polypharmacology in Precision Oncology: Identification of Differential Kinase Off-targets Among Clinical PARP Inhibitors
Poster Nov 08, 2017
Dr. Albert A. Antolin, Dr. Jordi Mestres, Prof. Paul Workman and Dr. Bissan Al-Lazikani
A more comprehensive and systems-based approach to pharmacology is uncovering that drugs tend to bind to more than one target, a behaviour commonly referred to as polypharmacology with clinical implications that are still not well understood.1
The increasing availability of ligand-target interaction data in the public domain in resources such as canSAR2 enables the development of computational methods to predict polypharmacology, that are becoming a cost-effective means to uncover new targets of drugs. PARP inhibitors are a new class of targeted small-molecule cancer therapeutics that have shown unexplained differential effects in cellular models and clinical trials.3
Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?
(1) Jalencas X, Mestres J. On the origins of drug polypharmacology. Med. Chem. Commun.,4, 80-87 (2013).
(2) Tym JE, Mitsopoulos C, Coker EA, Razaz P, Schierz AC, Antolin AA, Al-Lazikani B. CanSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 44, D938-43 (2016).
(3) Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget. 5, 3023-8 (2014).
We show that network analysis of co-localized ions from mass spectrometry imaging data provides a detailed chemo-spatial insight into the metabolic heterogeneity of tumors. Furthermore, module preservation analysis between colorectal cancer patients with and without metastatic recurrence suggests hypotheses on the nature of the different local metabolic pathways.READ MORE
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma. AITL can be missed until lymphadenopathy develops in patients initially presenting with skin lesions, as skin biopsy may lack conclusive findings. Our case highlights the extranodal presentation of AITL with cutaneous lesions displaying the TFH phenotype.READ MORE